← All trials
NCT01565278
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2012
- Primary completion
- Aug 1, 2015
- Completion date
- Aug 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 2
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of TorontoLead sponsor
- University of AlbertaCollaborator
- Hamilton Health Sciences CorporationCollaborator
- University of ManitobaCollaborator
- FreseniusCollaborator
- University of British ColumbiaCollaborator
- University of TorontoOverall official - principal investigator
- University of CalgaryCollaborator
- University of TorontoSponsor investigator
- ASPEN Rhoads Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.